BRAF and neoplasm: OS rates at 7.5 years were 57%, 42%, and 25% in patients with BRAF-mutant tumours and 43%, 41%, and 21% in patients with BRAF wild-type tumours in the nivolumab–ipilimumab, nivolumab, and ipilimumab treatment arms, respectively.